TR Talks: Challenges and Promises in Clinical Trials for Orphan Populations
Feb 12, 2019: Challenges and Promises in Clinical Trials for Orphan Populations
Successful progression through clinical trials requires not only the generation of evidence but also the ability to navigate regulations and associated administrative requirements. This week TR talk brings together a panel of experts to share their experiences from the front lines of clinical trials. Their failures successes and everything they learned along the way.
- Ms. Pat Furlong, FOunding President and CEO, Parent Project Muscular Dystrophy (PPMD)
- Dr. Daniel Morgenstern, Director, New Agent and Innovative Therapy Program (NAIP), Hematology/Oncology, SickKids
- Dr. Richard Sugarman, Chair, Ontario Cancer Research Ethics Board
- Dr. Mark Kieran, Clinical Trial Lead, Pediatrics Program Oncology Clinical Development, Bristol-Myers Squibb